Vascular disrupting agent for neovascular age related macular degeneration: a pilot study of the safety and efficacy of intravenous combretastatin A-4 phosphate.

Citation data:

BMC pharmacology & toxicology, ISSN: 2050-6511, Vol: 14, Issue: 1, Page: 7

Publication Year:
2013
Usage 62
Abstract Views 34
Downloads 28
Captures 1
Readers 1
Citations 17
Citation Indexes 17
Repository URL:
http://digitalcommons.unmc.edu/com_eye_articles/3
PMID:
23316779
DOI:
10.1186/2050-6511-14-7
PMCID:
PMC3552984
ClinicalTrials.gov Identifier:
NCT01570790
Author(s):
Ibrahim, Mohamed A.; Do, Diana V.; Sepah, Yasir J.; Shah, Syed M.; Van Anden, Elizabeth; Hafiz, Gulnar; Donahue, J. Kevin; Rivers, Richard; Balkissoon, Jai; Handa, James T.; Campochiaro, Peter A.; Dong Nguyen, Quan Show More Hide
Publisher(s):
Springer Nature
Tags:
Pharmacology, Toxicology and Pharmaceutics; Medicine; Angiogenesis; Neovascularization; Ocular pharmacology; Retinal degeneration; Combretastatin A-4 Phosphate; CA4P; Vascular disrupting agents; VDA; Ophthalmology
article description
This study was designed to assess the safety, tolerability, and efficacy of intravenous infusion of CA4P in patients with neovascular age-related macular degeneration (AMD).